ZG-005 is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase II drugs for Neuroendocrine Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ZG-005 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZG-005 overview
ZG-005 is under development for the treatment of solid tumors including cholangiocarcinoma, hepatocellular carcinoma, non-small cell lung cancer, small-cell lung cancer, esophageal squamous cell carcinoma, neuroendocrine carcinoma, cervical cancer, triple-negative breast cancer, bile duct cancer (cholangiocarcinoma) and soft tissue sarcoma. It is a bi-specific monoclonal antibody. It is administered through intravenous in the form of powder. It acts by targeting PD-1 and TIGIT.
Suzhou Zelgen Biopharmaceutical overview
Suzhou Zelgen Biopharmaceutical (Zelgen) is a pharmaceutical company that carries out research and development and production of innovative medicines. The company’s pipeline products include Donafenib Tablet, Rh Thrombin, gecacitinib hydrochloride tablets, ZG0895, ZGS15, ZG006, ZG2001, ZG1905, ZGGS001, RhTSH and gecacitinib hydrochloride Cream, ZG19018 Tablet, ZG005 Powder for Injection and ZGGS18. Its therapeutic areas include liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal cancer, myeloproliferative neoplasms cancers, hematological tumors, hemorrhage, immune-inflammatory diseases, liver and gallbladder diseases and other therapeutic areas. Zelgen operates its drug research and development center in China and the US. Zelgen is headquartered in Kunshan, Jiangsu, China.
For a complete picture of ZG-005’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
